Importance of N-Terminal Residues in Plasminogen Activator Inhibitor 1 on its Antibody Induced Latency Transition

Summary

The serpin plasminogen activator inhibitor-1 (PAI-1) is a wellknown risk factor for thromboembolic and cardiovascular diseases. Many efforts have been made to reveal structure-function relationship in PAI-1, including the understanding of its unique latency transition. In this study, we describe the molecular characterization of PAI-1 neutralization by MA-159M12, a monoclonal antibody against rat PAI-1.

Time-dependent inactivation of PAI-1, exposure of a trypsin cleavage site typically for the latent conformation and disappearance of elastase susceptibility revealed that MA-159M12 accelerated the active to latent, conformational transition (t_1/2 120 ± 12 min and 18 ± 3.6 min in the absence and presence of MA-159M12, p <0.0001).

Cross-reactivity analysis of the antibody with various rat/human PAI-1 chimeras revealed that the epitope resides in αhA of rat PAI-1. Subsequent alanine-scanning mutagenesis and binding studies demonstrated that Pro²- Leu³- Pro⁴-Glu⁵ constitute the major residues of the epitope for MA-159M12. In conclusion, these findings demonstrate that, even though unexpected based on current knowledge on PAI-1 stability and function, interference with αhA results in a destabilisation of its active, inhibitory conformation. Therefore, αhA forms a putative target for the rational development of PAI-1 neutralizing components.

Keywords

PAI-1 - monoclonal antibody - serpin - thrombosis

• References

• 1 Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1985; 260: 11581-7.
• 2 Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, Gerard RD, Goldsmith EJ. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992; 355: 270-3.
• 3 Declerck PJ, Juhan-Vague I, Felez J, Wiman B. Pathophysiology of fibrinolysis. J Intern Med 1994; 236: 425-32.
• 4 Juhan-Vague I, Alessi MC. Fibrinolysis and risk of coronary artery disease. Fibrinolysis 1996; 10: 127-36.
• 5 Nordt TK, Peter K, Ruef J, Kubler W, Bode C. Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease. Thromb Haemost 1999; 82 suppl 1: 14-8.
• 6 Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin α _vβ₃ binding to vitronectin. Nature 1996; 383: 441-3.
• 7 Kjoller L, Kanse SM, Kirkegaard T, Rodenburg KW, Ronne E, Goodman SL, Preissner KT, Ossowski L, Andreasen PA. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997; 232: 420-9.
• 8 Björquist P, Ehnebom J, Inghardt T, Deinum J. Epitopes on plasminogen activator inhibitor type-1 important for binding to tissue plasminogen activator. Biochim Biophys Acta 1997; 1341: 87-98.
• 9 Debrock S, Declerck PJ. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms. Biochim Biophys Acta 1997; 1337: 257-66.
• 10 Ngo TH, Bijnens AP, Knockaert I, Declerck PJ. Expression, purification and characterization of recombinant rat plasminogen activator inhibitor-1. Fibrinolysis 1997; 11: 37-43.
• 11 Verhamme I, Kvassman JO, Day D, Debrock S, Vleugels N, Declerck PJ, Shore JD. Accelerated conversion of human plasminogen activator inhibitor-1 to its latent form by antibody binding. J Biol Chem 1999; 274: 17511-7.
• 12 Bijnens AP, Gils A, Knockaert I, Stassen JM, Declerck PJ. Importance of the hinge region between α-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor Type 1 neutralizing antibodies. J Biol Chem 2000; 275: 6375-80.
• 13 Bijnens AP, Ngo TH, Gils A, Dewaele J, Knockaert I, Stassen JM, Declerck PJ. Elucidation of the binding region of PAI-1 neutralizing antibodies using chimeric variants of human and rat PAI-1. Thromb Haemost 2001; 85: 866-74.
• 14 Schousboe SL, Egelund R, Kirkegaard T, Preissner KT, Rodenburg KW, Andreasen PA. Vitronectin and substitution of a β-strand 5A lysine residue potentiate activity-neutralization of PA inhibitor-1 by monoclonal antibodies against α-helix F. Thromb Haemost 2000; 83: 742-51.
• 15 Stoop AA, Jespers L, Lasters I, Eldering E, Pannekoek H. High density mutagenesis by combined DNA shuffling and phage display to assign essential amino acids in protein-protein inter actions: application to study structurefunction of plasminogen activator inhibitor 1. J Mol Biol 2000; 301: 1135-47.
• 16 Ngo TH, Hoylaerts MF, Knockaert I, Brouwers E, Declerck PJ. Identification of a target site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitory properties concomitant with an allosteric up-regulation of its antiadhesive properties. J Biol Chem 2001; 276: 26243-8.
• 17 Debrock S, Declerck PJ. Identification of a functional epitope in plasminogen activator inhibitor-1, not localized in the reactive center loop. Thromb Haemost 1998; 79: 597-601.
• 18 Carrell RW, Stein PE. The biostructural pathology of the serpins: critical function of sheet opening mechanism. Biol Chem Hope Seyler 1996; 377: 1-17.
• 19 Gils A, Knockaert I, Declerck PJ. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop. Biochemistry 1996; 35: 7474-81.
• 20 Ngo TH, Verheyen S, Knockaert I, Declerck PJ. Monoclonal antibodybased immunoassays for the specific quantitation of rat PAI-1 antigen and activity in biological samples. Thromb Haemost 1998; 79: 808-12.
• 21 Jonsson U, Fagerstam L, Lofas S, Stenberg E, Karlsson R, Frostell A, Markey F, Schindler F. Introducing a biosensor based technology for real-time biospecific interaction analysis. Ann Biol Clin Paris 1993; 51: 19-26.
• 22 Lawrence DA, Palaniappan S, Stefansson S, Olson ST, Francis-Chmura AM, Shore JD, Ginsburg D. Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin: implications for the regulation of pericellular proteolysis. J Biol Chem 1997; 272: 7676-80.
• 23 Kjoller L, Martensen PM, Sottrup-Jensen L, Justesen J, Rodenburg KW, Andreasen PA. Conformational changes of the reactive centre-loop and-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen activator inhibitor-1. Eur J Biochem 1996; 241: 38-46.
• 24 Gils A, Declerck PJ. Structure-function relationships in serpins: current concepts and controversies. Thromb Haemost 1998; 80: 531-41.
• 25 Nar H, Bauer M, Stassen JM, Lang D, Gils A, Declerck PJ. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implication for serpin inactivation. J Mol Biol 2000; 297: 683-95.
• 26 Egelund R, Schousboe SL, Sottrup-Jensen L, Rodenburg KW, Andreasen PA. Type-1 plasminogen activator inhibitor. Conformational differences between latent, active, reactive-centre-cleaved and plasminogen activator complexed forms, as probed by proteolytic susceptibility. Eur J Biochem 1997; 248: 775-85.
• 27 Wardell MR, Chang WS, Bruce D, Skinner R, Lesk AM, Carrell RW. Preparative induction and characterization of L-antithrombin: a structural homologue of latent plasminogen activator inhibitor-1. Biochemistry 1997; 36: 13133-42.
• 28 Stout TJ, Graham H, Buckley DI, Matthews DJ. Structures of active and latent PAI-1: A possible stabilizing role for chloride ions. Biochemistry 2000; 39: 8460-9.
• 29 Aertgeerts K, De Bondt HL, De Ranter CJ, Declerck PJ. Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1. Nat Struct Biol 1995; 02: 891-7.
• 30 Sharp AM, Stein PE, Pannu NS, Carrell RW, Berkenpas MB, Ginsburg D, Lawrence DA, Read RJ. The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure Fold Des 1999; 07: 111-8.
• 31 Stoop AA, Eldering E, Dafforn TR, Read RJ, Pannekoek H. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries. J Mol Biol 2001; 305: 773-83.
• 32 Alessi MC, Declerck PJ, De Mol M, Nelles L, Collen D. Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1). Eur J Biochem 1988; 175: 531-40.
• 33 Zeheb R, Gelehrter TD. Cloning and sequencing of cDNA for the rat plasminogen activator inhibitor-1. Gene 1988; 73: 459-68.
• 34 Declerck PJ, Verstreken M, Collen D. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thromb Haemost 1995; 74: 1305-9.
• 35 Bijnens AP, Knockaert I, Cousin E, Kruihof EKO, Declerck PJ. Expression and characterization of recombinant porcine plasminogen activator inhibitor-1. Thromb Haemost 1997; 77: 350-6.